Besides, side effects could interfere with food preferences, leading to suboptimal intake of specific foods
June 17 Product: Biotests Yimmugo Indication: Primary immunodeficiencies Grifols subsidiary Biotest got the FDAs green light for its first U.S.-approved medicine, Yimmugo, an intravenous immunoglobulin (Ig) therapeutic, to treat primary immunodeficiencies
Some products may not mix well with drugs or other natural products
This is the primary safety concern: Symptoms: shakiness, lightheadedness, diaphoresis (sweating), mental fog, and in severe cases loss of consciousness
From refill questions to dose adjustments, our team responds within 24 hours